Clinical-Stage Companies / Quince

Quince

Pre-Approval PRO BETA

🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 12/11/2024

Total Trials

Phase 3

Phase 2

Recruiting

Score

Pipeline by Phase

Phase 3

Phase 2

Phase 1

Therapeutic Focus

Ataxia Telangiectasia Genetic Syndrome Healthy Nervous System Disorder Crohn's Disease

Clinical Trials (8)

NCT06664853 Phase 3 TERMINATED

Open-Label Extension of EryDex Study IEDAT-04-2022

Started: 12/11/2024

NCT06193200 Phase 3 COMPLETED

Evaluate the Neurological Effects of EryDex on Subjects With A-T

Started: 6/24/2024

NCT03563053 Phase 3 TERMINATED

Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study

Started: 6/12/2018

NCT01277289 Phase 3 TERMINATED

Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease

Started: 6/3/2009

NCT02770807 Phase 3 COMPLETED

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients

Started: 3/2/2017

NCT01255358 Phase 2 COMPLETED

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients

Started: 2/1/2011

NCT02380924 Phase 1 COMPLETED

Recovery and Survival of EryDex in Non-patient Volunteers

Started: 1/1/2015

NCT01925859 Phase 1 COMPLETED

EryDex Pharmacokinetics in Healthy Volunteers

Started: 6/1/2013

Drug Candidates

Dexamethasone sodium phosphate Dexamethasone EryDex Low dose DSP EryDex High dose DSP Pooled Placebo DSP loaded RBC using EryDex System Sham treated RBC using the EryDex System EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)

Activity Status: Slowing

Last Trial Started: 12/11/2024

Last Trial Ended: 1/30/2026

Trials (12 months): 0

Completed Trials: 5

Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.